Cancer Clinical Trials Information Platform in Hong Kong

  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials

Cancer Site

*in alphabetical order (Last updated on 6/11/2020)


Institution Study Title  
QMH Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting (NEOPRIMA) Click for Details
CUHK Melanoma
An open-label phase II study of pembrolizumab in East Asian patients with advanced/metastatic acral lentiginous melanoma
Click for Details
CUHK Biliary Tract Cancer
A Phase 3, Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine / Cisplatin versus Placebo Plus Gemcitabine / Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
Click for Details
CUHK Biliary Tract Cancer
A Phase III Randomized, Double-Blind, Placebo-Controlled,Multi-Regional, International Study of Durvalumab in Combination withGemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plusCisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)
Click for Details
HKU Gastrointestinal tumor
A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects with Advanced Gastrointestinal Tumors
Click for Details
HKU Thyroid Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy
Click for Details
PYNEH, PWH Blood Cancer
Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Click for Details
QEH Urothelial Cancer
A Phase 3, Multicenter, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy
Click for Details

For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.